For following the competition: what moved in each program, several studies read as one move.
- remibrutinib
- barzolvolimab
- TLL-018
- + 23 more
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add Chronic Urticaria to watchlistEvery Monday by email · turn it off any timePro · free during the beta